Preeclampsia (PE) is a serious hypertensive disorder affecting 4–5% of pregnancies
globally, leading to maternal and perinatal morbidity and mortality and reducing life …

Background: The process of lysosomal biogenesis and exocytosis in preeclamptic placentae
plays a role in causing maternal endothelial dysfunction. However, the specific lysosome …

The pathophysiology of preeclampsia (PE) is poorly understood; however, there is a large
body of evidence that suggests a role of immune cells in the development of PE. Amongst …

Antihypertensive therapy is an essential part of management of patients with preeclampsia
(PE). Methyldopa (Dopegyt®) and nifedipine (Cordaflex®) are basic medications of therapy …

Extracellular vesicles (EVs) can intercellularly transmit a wide range of bioactive molecules,
and these cargoes may potentially serve as therapeutic biomarkers for preeclampsia …

Background. Preeclampsia (PE), which has a high incidence rate worldwide, is a potentially
dangerous syndrome to pregnant women and newborns. However, the exact mechanism of …

The endothelium is a biologically active interface with multiple functions, some of them
common throughout the vascular tree, and others that depend on its anatomical location …

Preeclampsia (PE) is a pregnancy-specific hypertensive disorder with end-organ damage
that presents after 20 wk of gestation. PE pathophysiology often includes vascular …

Successful pregnancy requires an immunological shift with T helper CD4+ bias based on
disbalance Th1/Th17 versus Th2/T regulatory (Tregs) required to induce tolerance against …

Background Preeclampsia is a kind of pregnancy-related hypertension that affects 5.47% of
pregnancies in Ethiopia and 18.25% of pregnant women who visit Arba Minch public health …